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All known human adenoviruses are classified as mastadenoviruses, while the ovine adenovirus (OAdV) serotype 7 is the
prototype of the atadenoviruses, a proposed new genus. OAdV replicates abortively in human cell types and has potential
as a gene transfer vector. However, the function of OAdV nonstructural genes is poorly understood and it is unclear whether
OAdV replication might be complemented by a replicating human AdV in coinfected cells. To investigate possible interactions
three human cell lines were singly infected with OAdV or human AdV5 or doubly infected. The development of a cytopathic
effect and genome replication was monitored over three passages in each cell type. No significant OAdV replication occurred
in any of the cell types examined either in the presence or in the absence of replicating AdV5. No aberrant AdV5 genome
products were detected in coinfected cells. In contrast, in coinfected cells an OAdV recombinant that expressed the AdV5
E1A gene was able to promote the replication of an AdV5 E1A-deficient mutant, demonstrating trans-complementationINTRODUCTION
The ovine adenovirus (OAdV) isolate OAdV287 (Boyle
et al., 1994) is the prototype of a proposed new genus of
viruses referred to as the atadenoviruses (Benko and
Harrach, 1998; Both, 2001). OAdV has a narrow host
range but replicates efficiently in a primary ovine fetal
lung cell line, CSL503 (Boyle et al., 1994). This cell line is
also efficiently infected by AdV5 (Xu and Both, 1998) and
presumably, therefore, expresses the CAR receptor (Ber-
gelson et al., 1998; Tomko et al., 1997). The receptor for
OAdV has not been identified but is distinct from CAR
because AdV5 and OAdV do not compete for entry into
CSL503 cells (Xu and Both, 1998). Nevertheless, OAdV
infects a range of human cell types that are also infected
by AdV5, but replication is abortive (Khatri et al., 1997).
Depending on the cell type, individual OAdV promoters
may be active or inactive, but in all non-ovine cell types
examined, the major late promoter (MLP) is not detectably
active and no virus is produced (Khatri et al., 1997). How-
ever, OAdV promoters are not well characterized and the
basis for their (in)activity in different cell types is not under-
stood. In addition, OAdV lacks an E1A gene homologue and
does not have transforming ability in cells that are trans-
formed by AdV5 E1A/B sequences (Xu et al., 2000), but
homologues of E1B and E4 genes appear to be present in
the genome (Vrati et al., 1996a). Several other reading
1 To whom correspondence and reprint requests should be ad-333frames that encode putative proteins of unknown function
are also present (reviewed in Both, 2001).
Recombinant OAdVs have been constructed (Vrati et
al., 1996b; Xu et al., 1997) to assess the potential of the
virus as a gene delivery vector (Lo¨ser et al., 2000). Per-
ceived advantages are that OAdV is not neutralized by
random human antisera that neutralize AdV5 and that the
vector has an in vivo cell tropism that differs from AdV5
(Hofmann et al., 1999), which may offer new cellular
targets for gene delivery. Because the carrying capacity
of OAdV exceeds that of AdV5 (Xu et al., 1997) expression
cassettes have generally been inserted into the OAdV
genome without a compensating deletion. Thus, most
OAdV vectors retain their full gene complement and the
issue of where the replication cycle is blocked in human
cells and whether it can be complemented in trans is a
potential safety issue. Coinfection of cells by a replica-
tion-competent human AdV that expresses E1A proteins
might produce unintended consequences because E1A
products interact with numerous cellular proteins to ac-
tivate a variety of viral and cellular promoters (Liu and
Green, 1994; and reviewed in Shenk, 1996). Here we
investigated whether there was any detectable interac-
tion between OAdV and AdV5, manifested at the level of
viral replication, during coinfection of three different cell
types. The ability of an OAdV recombinant that ex-
pressed the AdV5 E1A gene to complement a replication-
deficient virus that lacked E1A function (Jones and
Shenk, 1979) was also examined. Our findings have posi-between appropriate viruses. These findings have implicati
enhancing gene delivery. © 2002 Elsevier Science (USA)
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fective human Ad vector may be enhanced in trans by
delivery of the appropriate gene using an OAdV vector.
RESULTS
Infection of MCF7 cells
The potential for interaction between ovine adenovirus
OAdV623, a recombinant that carries the complete ge-
nome plus an expression cassette (see Materials and
Methods), and a replicating human adenovirus, typified
by AdV5, was first investigated using MCF7 cells. After
infection of these cells with OAdV623 at m.o.i. 70 no
significant cytopathic effect (cpe) was seen after 4 days
(Fig. 1A). Following a further two (Fig. 1B) or three pas-
sages (not shown) OAdV623 again failed to produce cpe.
However, infection of MCF7 cells with OAdV217A, which
expresses GFP, proved that these cells were infected by
OAdV (Fig. 2), confirming earlier work (Khatri et al., 1997).
In contrast to OAdV, infection by AdV5 produced a com-
plete cpe after 4 days at m.o.i.s of 0.1 and 1.0 (Fig. 1A) and
cpe was also observed after a further two passages
(Fig. 1B).
After initial infection the AdV5 genome replicated with
an efficiency that was easily detectable by ethidium
bromide staining (Fig. 3A, lanes 9 and 10). However, the
OAdV623 genome replicated to a level that was greater
than input DNA (lanes 2, 5, and 6) but barely detectable,
even with a radiolabeled whole-genome probe (Fig. 3B,
lanes 8, 11, and 12). After two passages in MCF7 cells
AdV5 DNA remained detectable by staining (Fig. 3C,
FIG. 1. Single or double infection of MCF7 cells with OAdV623 and AdV5. Cells were infected with OAdV623 (70 TCID50/cell) or AdV5 (0.1 or 1.0
TCID50/cell) as indicated or with both viruses at the same m.o.i. At 4 days postinitial infection (A) or after two passages (B), viable cells were fixed
and stained with crystal violet.
FIG. 2. Infection of MCF7 cells with an ovine adenovirus that ex-
presses green fluorescent protein. Cells were infected with OAdV217A
at 102–105 vp/cell, as indicated, and examined by fluorescence micros-
copy at day 4. The lower right-hand panel shows the corresponding
phase image of the adjacent panel.
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lanes 9–12) while OAdV DNA was no longer detectable,
even with the radiolabeled probe (Fig. 3D, lanes 8, 11,
and 12). No aberrant AdV5 bands were observed after
replication in the presence of the OAdV623 genome
following one, two (Figs. 3A and 3C, lanes 11 and 12), or
three passages (data not shown). It is estimated from the
plasmid standards that the radiolabeled whole-genome
OAdV probe used in Fig. 3B would have detected in the
range of 150–1500 genome copies per cell (10 ng of
OAdV plasmid DNA is 3  108 genome copies). Thus,
if a segment comprising 10% of the OAdV genome had
been incorporated into a replicating hybrid AdV5 ge-
nome, approximately 1500 copies/cell would have been
detectable.
Infection of HeLa and MRC5 cells
The same experiment was carried out in HeLa and
MRC5 cells as these are also infected by both viruses
(Khatri et al., 1997; and data not shown). In HeLa cells
results essentially identical to those obtained with MCF7
cells were obtained; i.e., the OAdV623 genome did not
replicate. However, in MRC5 cells infected with OAdV at
high multiplicity (m.o.i. 70), cpe appeared by day 4 as
previously reported (Khatri et al., 1997). This reduced the
level of AdV5 replication in doubly infected cells com-
pared with AdV5 infection alone. Again, Southern analy-
sis showed that the OAdV623 genome did not replicate
significantly in these cells after initial infection. Thus, the
apparent cpe was not due to replication and the virus did
not passage. In subsequent passages on MRC5 cells
AdV5 replicated normally and the HindIII pattern was
unchanged. Southern analysis showed that no portion of
the OAdV genome was detectably incorporated into a
replicating AdV5 genome (data not shown).
Rescue and characterization of an OAdV recombinant
expressing the AdV5 E1A gene
The apparent lack of interaction between OAdV and
AdV5 suggested that it would be possible to use OAdV to
deliver a gene to complement defective AdV5 replication
in coinfected cells. A positive outcome from such an
experiment would also act as a control for the negative
results obtained above. Therefore a plasmid in which the
E1A gene and promoter were inserted into nonessential
reading frame RH2 at the right-hand end of the OAdV
genome was constructed (Xu et al., 1997) and virus
FIG. 3. Analysis of low-molecular-weight DNA extracted from MCF7 cells at 4 days postinfection. Analysis was performed following initial (A, B) and
passage 2 infection (C, D). In (A) and (C) DNA was analyzed by staining with ethidium bromide. In (B) and (D) DNA was analyzed by hybridization with
a whole-genome OAdV probe derived from plasmid OAdV220. The probe also cross-hybridized with AmpR sequences common to plasmid pJM17 that
contains the AdV5 genome (McGrory et al., 1988). Cells were uninfected (C) or infected with OAdV623 at m.o.i. 70 and AdV5 at m.o.i. 1.0 (H) and 0.1
(L) as indicated.
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OAdV619B was rescued. The genome of this virus had
the expected pattern of BamHI fragments (Fig. 4) in that
the plasmid band of 17.8 kb was converted to fragments
of 10.3 and 4.2 kb in the virus (the prokaryotic fragment of
3 kb was lost). Expression of the E1A gene after infec-
tion of permissive CSL503 cells by OAdV619B was con-
firmed by immunofluorescence using an E1A-specific
monoclonal antibody (Fig. 5). Similar attempts to demon-
strate E1A expression in HeLa and MCF7 cells in which
OAdV does not replicate did not produce a fluorescent
signal above background (data not shown).
Complementation of a defective AdV5 mutant
The ability of OAdV619B to complement AdV dl312
replication was first examined in HeLa cells. Compared
FIG. 4.Map and profile of the OAdV619B viral genome. The AdV5 E1A gene was inserted into unique NotI/ApaI sites engineered into open reading frame
RH2. Following transfection into CSL503 cells the genome of the virus (V) rescued was characterized by digestion with BamHI and compared to the plasmid
(P) from which it was derived. Lane M contains  EcoRI/HindIII markers. The smallest band in lane 1 is derived from ovine repetitive DNA.
FIG. 5. Detection of AdV5 E1A gene expression by recombinant OAdV619B in permissive CSL503 cells. Cells were infected with wild-type OAdV
or OAdV619B at m.o.i. 10 and E1A expression was detected by immunofluorescence after 24 h.
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to uninfected cells (Fig. 6A, well 1), the cell monolayer
was also preserved at day 3 postinfection after HeLa
cells were singly infected with m.o.i. 10 of AdV dl312 or
OAdV619B (wells 2 and 3) or with m.o.i. 10 or 100 of
wild-type OAdV (wells 7 and 8). Cells infected with wild-
type AdV5 (0.1 TCID50/cell) remained relatively intact at 3
days (well 9) but at m.o.i. 1.0 (well 10) severe cpe was
evident as expected. Coinfection with wild-type OAdV
and AdV dl312 at m.o.i. 100 and 5 TCID50/cell, respec-
tively, produced no obvious cpe (well 6). In contrast,
FIG. 6. Complementation of AdV dl312 replication in HeLa cells by coinfection with OAdV619B. In (A) cells in wells 1–10 were singly infected with
OAdV619B, wild-type OAdV, or AdV dl312 at the m.o.i. indicated in italics or coinfected at the same m.o.i. Residual viable cells were stained with crystal
violet at 4 days postinfection. In (B) low-molecular-weight DNA from cultures infected as in (A) was digested with HindIII and analyzed by agarose
gel electrophoresis and staining with ethidium bromide.
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coinfection with m.o.i. 5 or 50 of AdV dl312 plus
OAdV619B produced extensive or total cpe, respectively
(wells 4 and 5), suggesting that AdV dl312 had replicated
due to trans-complementation by E1A. This was con-
firmed by analysis of the corresponding DNA samples
from duplicate cells infected as in Fig. 6A. Ethidium
bromide staining (Fig. 6B) showed that no HindIII bands
were detected in mock-infected cells (lane 1) or cells
singly infected with AdV dl312 (lane 2), OAdV619B (lane
3), or wild-type OAdV (lanes 6 and 7). Consistent with the
lack of cpe observed above, viral DNA replication was
also not detected in cells coinfected with m.o.i. 50 of AdV
dl312 and wild-type OAdV (lane 8). However, AdV dl312
genome replication occurred in the presence of both low
(m.o.i. 5) and higher (m.o.i. 50) inputs of OAdV619B (lanes
4 and 5). The presence of the 1.9-kb G band rather
than the larger band G is diagnostic for AdV dl312 (Jones
and Shenk, 1979). The level of AdV dl312 DNA replication
at the higher m.o.i. approximated that seen following
infection with wild-type AdV5 at m.o.i. 1.0 (lane 10).
The ability of OAdV619B to complement AdV dl312
replication was quantitated by determining virus titers. At
day 4 the titer of virus present in the medium of HeLa
cells infected with AdV dl312 alone was 108 TCID50/ml of
AdV dl312 when assayed on 911 cells (Table 1). However,
in the presence of an increasing input of OAdV619B AdV
dl312 titers increased by up to 2 log10 (Table 1).
Similar experiments were carried out in MCF7 cells
and viral titers were again monitored. In several experi-
ments in the presence of OAdV619B AdV dl312 titers
again increased over input virus by a maximum of 100-
and 200-fold at 3 and 6 days postinfection, respectively
(Table 1, Fig. 7), showing that complementation of AdV
dl312 replication had also occurred in this cell line. In
addition, when the products from these mixed infections
were passaged on MCF7 cells in the absence of freshly
added OAdV619B, AdV dl312 titers decreased signifi-
cantly (Fig. 7), as expected for the passage of defective
viruses.
DISCUSSION
OAdV is the prototype of the proposed atadenovirus
genus (Benko and Harrach, 1998) and for a variety of
reasons, including its neutralization properties and in
vivo tropism (Both, 2002; Hofmann et al., 1999; Lo¨ser et
al., 2000), there is interest in developing the virus as a
gene transfer vector. There are numerous differences
between OAdV and the mastadenoviruses genomes but
comparatively little is known about the expression and
function of nonstructural genes carried by OAdV. An
overview transcription map of the genome has been
determined (Khatri and Both, 1998) but detailed analyses
of promoters and the transcription factors that control
them have not been carried out. OAdV replicates abor-
tively in the human cell types that have been tested
(Khatri et al., 1997) but the basis for this is not well
understood. In a future clinical situation involving gene
delivery by OAdV, coinfection by an adventitious human
adenovirus could have safety or efficacy implications.
Thus, AdV5 was selected as a typical human adenovirus
to investigate potential interactions between an OAdV
vector and a replication-competent virus.
As infection of human cells with OAdV often shows
little phenotypic effect (Khatri et al., 1997), OAdV217A
(Lo¨ser et al., 1999), a virus that expressed GFP, was used
to confirm infection of some cell lines. However, as
shown by restriction enzyme and PCR analyses the
HCMV/GFP reporter gene cassette inserted in a left to
right orientation in site I between pVIII and fiber has
proven to be unstable (Lo¨ser et al., 1999). In addition, the
viral major late promoter which might salvage expres-
sion is not active in human cells (Khatri et al., 1997).
Thus, OAdV217A must substantially underreport the ex-
tent of infection.
The outcome of coinfection with wild-type AdV5 and
OAdV623 was examined in three human cell lines with
essentially the same results. Although AdV5 replicated to
a high level as expected, the OAdV genome was not
FIG. 7. Titration of AdV dl312 stocks after initial infection and one
passage in MCF7 cells in the absence and in the presence of
OAdV619B. MCF7 cells were infected with m.o.i. 20 of AdV dl312 alone
or with increasing amounts of OAdV619B as indicated. Virus yields after
the initial and one further passage were assayed on 911 cells.
TABLE 1
Titers of AdV dl312 Produced in HeLa and MCF7 Cells
in the Presence and in the Absence of OAdV619B
OAdV619B
m.o.i.b





0 1 108 3.2 106
10 3.2 109 3.2 107
20 5.9 109 1.0 108
50 1 1010 1.7 107
100 1 1010 1.0 108
a TCID50/ml titered in 911 cells.
b TCID50/cell titered in CSL503 cells.
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significantly replicated after infection in the presence or
in the absence of replicating AdV5. Upon passage all
trace of OAdV replication was lost. This confirmed earlier
work (Khatri et al., 1997) and showed that abortive OAdV
replication in human cells was not complemented in
trans by any AdV5 gene product, in particular, by AdV5
E1A proteins. However, the effect of E1A expression, if
any, on the activity of individual OAdV promoters has not
been examined.
Several other differences between the OAdV and the
AdV5 genomes are consistent with the lack of comple-
mentation/interaction between the viruses (Fig. 8). Com-
pared to AdV5 (a prototype mastadenovirus), the OAdV
genome is characterized by a high A/T (low G/C) content,
ITRs that are distinct in both length and sequence, the
absence of structural proteins V and IX, and a reading
frame that encodes the structural protein p32 near the
left end of the genome. The distinctive base composition
reflects a low nucleotide sequence homology between
the two genomes that in turn minimizes the likelihood of
homologous recombination between them. Even if this
did occur, a single event would yield a hybrid genome
with nonidentical ITR sequences and one that would
encode an incomplete set of genes for either virus. In the
even more unlikely event of two recombination events a
genome with identical ITRs could be formed. Potentially
this could be amplified by the AdV5 DNA replication
machinery. However, the formation of aberrant AdV5 ge-
nomes was not observed in any of the cell lines exam-
ined, even after multiple passages to allow for genome
amplification. The implication from these experiments is
that if a virus such as AdV5 coinfected cells containing
an OAdV vector, the outcome may well be inconsequen-
tial. Together with the lack of transforming ability of OAdV
(Xu et al., 2000), these data have important positive
implications for the biosafety of OAdV vectors.
In contrast, to investigate whether complementation
between compatible genomes could occur we deter-
mined whether an OAdV recombinant that carried the
AdV5 E1A gene and promoter could promote the repli-
cation of AdV dl312, an E1A-defective mutant (Jones and
Shenk, 1979). The finding that the replication of AdV dl312
increased in both HeLa and MCF-7 cells in response to
coinfection with an OAdV vector that expressed the miss-
ing gene provided an in-principle demonstration of trans-
complementation after coinfection. The positive result
also reinforced the lack of compatibility between OAdV
and AdV5 genomes implicit in the negative results de-
scribed above. This demonstration of trans-complemen-
tation is consistent with previous work which demon-
strated that genes delivered on a plasmid (Goldsmith et
al., 1994; Han et al., 1998; Imler et al., 1995; Oualikene et
al., 1995) or a coinfecting bovine adenovirus (Zheng et al.,
1994) could complement a defect in the AdV5 genome,
thus promoting limited replication.
As the replication-deficient virus was propagated in
293 cells that carry integrated E1A/B sequences (Gra-
ham et al., 1977) we considered whether contaminating
replication-competent AdV5 formed by recombination in
those cells might account for the increase in AdV dl312
titers. However, the same amount of AdV dl312 was
added to all cells and the effect of complementation by
OAdV619B was seen over and above the minimal repli-
cative capacity of AdV dl312 stocks in HeLa and MCF7
cells. The higher level of AdV dl312 recovered from HeLa
compared with MCF7 cells may reflect an ability of the
former cells to complement the E1A defect in the virus
due to the presence of papilloma virus E6/E7 sequences.
Despite the positive outcome for AdV dl312 replication,
the conditions for complementation in those experiments
may not have been optimal. It was demonstrated by
immunofluorescence that E1A proteins were expressed
in CSL503 cells during permissive infection by
OAdV619B although the level of expression was not
quantitated. However, E1A expression was not detect-
able by immunofluorescence in HeLa and MCF7 cells
where OAdV replication was abortive. Thus, the ob-
served complementation was probably achieved with a
very low level of E1A. By using a stronger constitutive
promoter to drive E1A expression complementation may
be enhanced. However, the effect would still be limited
by the relative abilities of both OAdV and AdV5 to enter
target cells. As the viruses appear to use distinct recep-
tors (Xu and Both, 1998) a deficiency in either receptor
would currently limit the applicability of mixed infection
to enhance replication.
In principle, the benign outcome of OAdV infection in
some cell types could be exploited to deliver a variety of
other genes whose products can complement in trans.
Expression of AdV5 E1A/B genes is an obvious choice to
amplify expression from many existing AdV5 vectors.
Construction of such an OAdV vector would be facilitated
by the removal of an internal KpnI site in the E1B gene
that was limiting in the present circumstances since
OAdV genomes are released from plasmids with that
enzyme (Vrati et al., 1996b). The delivery of E4 genes for
complementation may also be possible. Similarly, an
OAdV that expresses the CAR receptor (Bergelson et al.,
1998; Tomko et al., 1997) might also be used to render
FIG. 8. Difference map between the OAdV and the AdV5 genomes.
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CAR-negative, OAdV-receptor-positive cells susceptible
to infection by existing AdV5 vectors.
MATERIALS AND METHODS
Cells and viruses
CSL503 cells were obtained from CSL Ltd. (Parkville,
Victoria, Australia). MCF7 (human breast cancer), HeLa
(human cervical carcinoma), and MRC5 (human lung)
cells were obtained from ATCC and from Drs. R. Holliday
and P. Molloy at CSIRO (North Ryde, New South Wales,
Australia), respectively, and grown in DMEM high glu-
cose (Trace Biosciences, Castle Hill, New South Wales,
Australia) plus 10% FCS. For MCF7 cells, the FCS was
heat-inactivated and for MRC5 cells sodium pyruvate (1
mM) was also added. 911 cells (Fallaux et al., 1996) were
obtained from Introgene BV (Leiden, The Netherlands)
and grown in DMEM plus 10% heat-inactivated FCS.
Wild-type AdV5 was obtained from ATCC. AdV dl312,
obtained from Dr. A. Mullbacher (Australian National
University, Canberra) carries an E1A deletion and at low
multiplicity of infection is defective for replication (Jones
and Shenk, 1979). Recombinant virus OAdV217A that
expresses green fluorescent protein was previously de-
scribed (Lo¨ser et al., 1999). Recombinant virus OAdV623
(to be described elsewhere) carries an expression cas-
sette that comprises a prostate promoter linked to the
Escherichia coli purine nucleoside phosphorylase cod-
ing sequences and a polyadenylation signal inserted in
the ApaI/NotI sites of plasmid pOAV600 (Xu et al., 1997).
This insertion was made at an intergenic site between
the transcription units for the right-hand end and the
proposed E4 regions (Khatri and Both, 1998). Virus
OAdV619B was constructed by inserting the AdV5 E1A
gene and promoter into nonessential reading frame RH2
of the OAdV genome (Xu et al., 1997) as follows. Plasmid
pOAV100 (Vrati et al., 1996b) was digested with SalI and
an oligonucleotide containing NotI/ApaI sites was in-
serted (pOAV608B). Plasmid pE1-FR1 (provided by Dr. R.
Garver, Gene Therapy Program, University of Alabama at
Birmingham) (Xu et al., 2000) containing AdV5 E1A and
E1B sequences in an inverted orientation was cut with
EcoRI and XhoI to release the E1A gene and promoter.
This fragment was bluntend-cloned into the XbaI site of
pGem11zf (Promega Corp., Madison, WI) and a clone
with the fragment in the NotI/ApaI orientation was se-
lected. The E1A sequences were subcloned into the
NotI/ApaI sites of pOAV608B to create plasmid
pOAV619B. This plasmid was digested with KpnI to re-
lease the linear OAdV genome and naked DNA was
transfected into CSL503 cells to rescue the correspond-
ing virus, OAdV619B (Vrati et al., 1996b). This virus con-
tains the E1A gene inserted within the nonessential open
reading frame RH2 (22.3 kDa) of the genome (Xu et al.,
1997). Wild-type OAdV, OAdV619B, and OAdV623 with
particle:infectious particle ratios of 100:1 were propa-
gated in CSL503 cells and purified by centrifugation in
CsCl density gradients (Boyle et al., 1994). Wild-type
AdV5 and AdV dl312 (ratios of 140:1 and 23:1, respec-
tively) were propagated in 293 cells and similarly purified
(Graham and Prevec, 1991). Viruses were titered in ap-
propriate cell lines by limiting dilution titration. Multiplic-
ity of infection therefore refers to TCID50/cell unless
specified otherwise.
Infection of cells
OAdV623 replication in the presence and in the ab-
sence of AdV5 was examined in MCF7, HeLa, and MRC5
cells. Cells were left uninfected or were infected in trip-
licate with70 TCID50/cell (10
4 virus particles (vp)/cell) of
OAdV623, or 0.1 or 1.0 TCID50/cell (7 or 70 vp/cell) of AdV5
or coinfected with the respective amounts of AdV5 and
OAdV623. One set of cells was harvested 3 h after
infection and low-molecular-weight DNA was extracted
as a control for input viral DNA. The remaining cells were
incubated for 4 days. One set was used for staining of
residual cells with crystal violet. A third set was used for
extraction of low-molecular-weight DNA that, along with
control samples, was subjected to restriction enzyme
digestion and analysis by agarose gel electrophoresis to
ascertain whether viral genome replication had oc-
curred. Medium from one set of cells was also retained
so that any virus produced by day 4 could be passaged
on fresh cells. Three passages were carried out.
To monitor interaction between OAdV619B and AdV
dl312, cells were singly or doubly infected and harvested
at days 3–6 postinfection as indicated for each experi-
ment. Cells were processed as described above or a
sample of the medium was taken for the determination of
AdV dl312 titers using a limiting dilution assay on 911
cells.
Immunofluorescence with M73
Monoclonal antibody M73 (Harlow et al., 1985) was
obtained from Dr. A. Mullbacher (Australian National
University, Canberra). E1A expression was detected by
immunofluorescence. Briefly, cells were washed in PBS,
fixed in 4% paraformaldehyde in PBS, washed again,
made permeable with 1:1 methanol:acetone, and
washed in PBS. A 1:5 dilution of M73 was added to cells
for 2 h at 37°C and excess antibody was removed by
washing with PBS. E1A/M73 complexes were detected
by fluorescence microscopy after being stained with
FITC-conjugated rabbit anti-mouse serum (Dako) (1 in 20
dilution).
Preparation and analysis of low-molecular-weight
DNA
At 3–5 days postinfection cells in the medium were
spun down and combined with residual attached cells.
Viral genomic DNA was recovered as previously de-
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scribed (White et al., 1984). Briefly, cells were treated
with pronase/SDS and residual DNA was recovered and
adjusted to 1 M NaCl to precipitate high-molecular-
weight DNA. Low-molecular-weight DNA was recovered
from the supernatant by precipitation with ethanol, di-
gested with HindIII, and analyzed by agarose gel elec-
trophoresis.
Preparation of genomic probes
Radiolabeled probes of the OAdV or AdV5 genomes
were prepared by using a Gigaprime kit (Geneworks,
Adelaide, South Australia, Australia) to randomly label 25
ng of the plasmids pOAdV220 or pJM17 (McGrory et al.,
1988), respectively. The latter plasmid comprises the
entire AdV5 genome with a prokaryotic insert in the E1
region. The restriction enzyme profiles of the plasmids differ
from those of the corresponding virus because the plas-
mids also carry a prokaryotic ampR gene and origin of DNA
replication. These are similar and cross-hybridize.
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